TNF biosynthesis in gut associated immunopathologies


Abstract
We addressed the impact of deleting TNF AU-rich elements (ARE) from the mouse genome on the regulation of TNF biosynthesis and the physiology of the host. Absence of the ARE affected mechanisms responsible for TNF mRNA destabilization and translational repression in hemopoietic and stromal cells. In stimulated conditions, TNF ARE were required both for the alleviation and reinforcement of message destabilization and translational silencing. Moreover, the mutant mRNA was no longer responsive to translational modulation by the p38 and JNK kinases, demonstrating that TNF ARE are targets for these signals. Development of two specific pathologies in mutant mice, i.e., chronic inflammatory arthritis and Crohn’s-like inflammatory bowel disease, suggests that defective function of ARE may be etiopathogenic for the development of analogous human pathologies.

Comment
There are a number of reasons why this paper is of interest to Gut readers. Firstly it provides new insights into the regulation of the proinflammatory cytokine tumour necrosis factor (TNF); secondly it shows that dysregulation of the TNF gene in mice leads to chronic inflammation of the joints and intestine; and thirdly there is evidence of differential roles for TNF receptors and the acquired immune response in joint and gut pathology. In addition, a useful mouse model of the human TNF gene. However a number of external factors, including viral proteins, can modulate the TNF ARE and hence may initiate some of the immunopathologies associated with this cytokine.

A 69 base pair deletion encompassing the TNF ARE (TNF ARE) was targeted in mouse embryonic stem cells and mice homozygous for this construct generated. These mice were also crossed with TNF−/− mice to give monoallelic TNF ARE without the influence of normal TNF production. Appreciable levels of TNF were found in blood of mice with the mutant construct but not in controls. Macrophages from the TNF ARE mice spontaneously secreted TNF and after stimulation with lipopolysaccharide, the mRNA half life was fourfold higher than in controls. T cells from TNF ARE mice also showed higher and sustained TNF-α release and the absence of the ARE rendered non-haemopoietic tissues permissive for TNF production.

The weight of the TNF ARE mice never exceeded 7 g and by 6–12 weeks of age they succumbed to chronic polyarthritic and inflammatory bowel disease. The gastrointestinal tract showed a Crohn’s disease-like phenotype, localised to the terminal ileum and occasionally the proximal colon. First there were mucosal abnormalities, with intestinal villus blunting and broadening. By 4 weeks of age in homozygous (8 weeks in hemizygous) mice there was severe intestinal inflammation deep into the muscular layers of the bowel wall with non-caseating granulomas. To investigate further the mechanisms of this immunopathology, the Kollias team crossed the TNF ARE mice with those lacking TNF receptors. TNF ARE/TNF-RI−/− mice developed normally with no signs of illness. This is no great surprise as most of the immune pathology involving TNF is thought to be mediated by TNF-RI, which is widely expressed on most cells. TNF-RII is restricted to cells of the haemopoietic system and the phenotype of the TNF ARE/TNF-RII−/− mice was more intriguing. They had an even more aggressive and destructive arthritis but their gut pathology was greatly reduced. The TNF ARE mice were also crossed with RAG1 deficient mice which lack T and B cells. Once again, the arthritic phenotype was maintained but the gut pathology abrogated.

In this model, the adaptive immune response and both TNF receptors were necessary for Crohn’s disease-like pathology in the presence of deregulated TNF. By contrast, the rheumatoid arthritis phenotype may have been driven by TNF-RII expressing synoviocytes that were spontaneously producing TNF.

As yet there are no known polymorphisms of the 3’ UTR of the human TNF gene. However a number of external factors, including viral proteins, can modulate the TNF ARE and hence may initiate some of the immunopathologies associated with this cytokine.

F Balkwill
Head, Biological Therapy Laboratory, Imperial Cancer Research Fund, Lincoln’s Inn Fields, London WC2A 3PX, UK
TNF biosynthesis in gut associated immunopathologies

F BALKWILL

Gut 1999 45: 483
doi: 10.1136/gut.45.4.483

Updated information and services can be found at:
http://gut.bmj.com/content/45/4/483

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/